Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, People's Republic of China.
College of Energy Engineering and State Key Laboratory of Fluid Power and Mechatronic Systems, Zhejiang University, Hangzhou 310027, Zhejiang Province, People's Republic of China.
J Biomed Nanotechnol. 2022 Mar 1;18(3):660-676. doi: 10.1166/jbn.2022.3297.
Hepatocellular carcinoma (HCC), due to the lack of efficient diagnostic methods and short of available treatments, becomes the third main cause of cancer deaths. Novel treatments for HCCs are thus in great need. The fast-growing area of drug delivery provides intriguing possibility to design nanocarriers with unique properties. The nanocarriers performanced as drug deliver vehicles enable the design of diverse drug delivery systems, which could serve multiple purposes, including improved bioavailability, controlled or triggered release and targeted delivery, leading to enhanced drug efficacy and lowered drug toxicity. This paper provides an overview on the types of delivery vehicles, functions of drug nanocarriers and types of ligand-based targeting systems and highlights the advances made towards better HCC treatments.
肝细胞癌 (HCC) 由于缺乏有效的诊断方法和有限的治疗手段，成为癌症死亡的第三大主要原因。因此，非常需要新的 HCC 治疗方法。药物输送这一日益发展的领域为设计具有独特性能的纳米载体提供了有趣的可能性。纳米载体作为药物输送载体的性能能够设计出多种药物输送系统，这些系统可以有多种用途，包括提高生物利用度、控制或触发释放和靶向输送，从而提高药物疗效和降低药物毒性。本文概述了输送载体的类型、药物纳米载体的功能以及基于配体的靶向系统的类型，并重点介绍了在改善 HCC 治疗方面取得的进展。
